Lallemand closes licensing deal with Proge Farm for its women’s health probiotic
Lallemand Health Solutions and Proge Farm closed a licensing deal for the commercialization of Proge Farm’s probiotic strain L. plantarum P17630 (Proge P17630), which has specific women health benefits.
Photo © iStockphoto.com/rzdeb
Lallemand Health Solutions (Mirabel, Canada) and Proge Farm (Novara NO, Italy) closed a licensing deal for the commercialization of Proge Farm’s probiotic strain L. plantarum P17630 (Proge P17630), which has specific women health benefits.
“Proge Farm’s highly documented probiotic strain L. plantarum P17630 is a valuable new asset in Lallemand Health Solution’s Women’s health probiotic range,” said Isabelle Champié, vice president sales and marketing at Lallemand Health Solutions, in a press release. “Women’s health is gaining more importance in the probiotics market, as consumers are increasingly looking for natural ways to take care of their intimate health. Furthermore, with this specific strain, it will be even easier to do so with one daily dose taken orally.”
Giancarla Dondi, owner and CEO of Proge Farm said Lallemand Health Solutions will be able to widely disseminate its probiotic strain, “meaning more women will benefit from its compelling effects,” she said in a press release.
The licensing commercialization agreement includes the following territories: Asia, Americas, France, and Czech Republic. Lallemand Health Solutions will launch this new offer in September at the Vitafoods Virtual Expo (Sept. 7-11, 2020).
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
